Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
Caspase-8-N4BP1 轴对促炎细胞因子反应的调节
基本信息
- 批准号:10704065
- 负责人:
- 金额:$ 44.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-13 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAffectAgonistAnti-Inflammatory AgentsApoptosisApoptoticAppointmentAreaAutoimmunityAwardBinding ProteinsBiochemistryBiological ProcessBiologyCASP8 geneCD95 AntigensCareer MobilityCaspaseCell Culture TechniquesCell DeathCellsCellular ImmunologyCessation of lifeClinicalClinical CompetenceClinical PathologyClustered Regularly Interspaced Short Palindromic RepeatsCommunicable DiseasesCompetenceDataDedicationsDiseaseDisease ProgressionEndowmentEvaluationFacultyFundingGene ExpressionGeneticGenetic TranscriptionGenetically Engineered MouseGoalsHealthHigh-Throughput Nucleotide SequencingHumanImageImmuneImmune System DiseasesImmunityImmunologic Deficiency SyndromesImmunologic ReceptorsImpairmentIn VitroInflammationInflammatoryInflammatory Response PathwayInstitutionKnock-inKnowledgeLaboratoriesLeadershipLicensingLigandsLinkMacrophageMalignant NeoplasmsMediatingMedicalMedicineMentorsMentorshipMolecularMutationNF-kappa BNatural ImmunityNerve DegenerationPathologicPathologyPathway interactionsPatientsPeer ReviewPhasePhosphotransferasesPhysiciansPositioning AttributePostdoctoral FellowProductionProteinsPublicationsRegulationResearchResearch PersonnelResearch ProposalsResidenciesResistanceRoleRotationScientistSeriesSignal PathwaySignal TransductionSourceStudentsSystemT-LymphocyteTBK1 geneTLR1 geneTLR3 geneTLR4 geneTLR7 geneTNF geneTNFSF6 geneTechniquesTechnologyTherapeutic InterventionToll-like receptorsTrainingTranscriptTransferable SkillsUnited States National Institutes of HealthUniversitiesVisitWorkadaptive immunityautoimmune lymphoproliferative syndromeautoinflammatory diseasescareerconstrictioncytokineexpectationexperiencefaculty supportgenome editinggenome-wideimmune activationin vivoinsightinstructormeetingsnew therapeutic targetnovelnovel therapeutic interventionphosphoproteomicsresponsesenior facultysingle cell analysisundergraduate student
项目摘要
Project Summary/Abstract
Rare monogenic immune disorders have illuminated key aspects of inflammation, but many of the underlying
mechanisms remain poorly understood. For example, autoimmune lymphoproliferative syndrome (ALPS), a
disorder in which T cells fail to undergo apoptosis, is most often caused by genetic defects in the death receptor
FAS or its ligand FASL. However, mutations in caspase-8 or its adaptor FADD – which mediate cell death
downstream of FAS – cause a combination of ALPS plus severe immunodeficiency. Since immunodeficiency is
not generally observed in patients with FAS or FASL mutations, I hypothesized that FADD-caspase-8 must have
an apoptosis-independent function downstream of an immune receptor other than FAS. Indeed, I recently
discovered that activation of multiple immune receptors elicits the caspase-8-mediated cleavage of Nedd4-
binding protein 1 (N4BP1), a novel cytokine suppressor. This represents a critical point of regulation during
inflammation. Notably, deletion of N4BP1 does not ordinarily affect the TRIF-dependent subset of toll-like
receptors (TLRs) that activate caspase-8 (e.g., TLR3 and TLR4). However, the impaired cytokine production of
caspase-8-deficient macrophages stimulated with a TLR4 agonist is restored to normal by co-deletion of N4BP1.
In contrast, N4BP1 deletion leads to exorbitant cytokine responses by the TRIF-independent TLRs (e.g., TLR1/2,
TLR7 and TLR9) that do not directly activate caspase-8. Thus, N4BP1 cleavage by caspase-8 inactivates the
anti-inflammatory activity of intact, un-cleaved N4BP1. These findings offer a novel mechanistic explanation for
immunodeficiency caused by FADD-caspase-8 mutations, whereby the inability to cleave N4BP1 results in its
aberrant persistence and constriction of cytokine responses. Like TLR3 and TLR4 agonists, tumor necrosis factor
(TNF) also leads to caspase-8 cleavage of N4BP1, endowing TNF with the ability to inactivate N4BP1 and
thereby license cytokine production by the TRIF-independent TLRs. This latter finding highlights a key point of
molecular crosstalk between the TNF and TLR systems that converges on caspase-8 cleavage of N4BP1. In the
current proposal, I have linked the mechanism by which N4BP1 suppresses cytokine production to a series of
proteins with both previously recognized and heretofore unknown roles in inflammation. In Aim 1, I will attempt
to decipher the mechanism by which N4BP1 controls the activity of this novel kinase-dependent pathway that
suppresses inflammation. In Aim 2, I will dissect how N4BP1 suppresses late phase inflammatory gene
expression using genome-scale technologies. In Aim 3, I will explore the mechanisms and in vivo consequences
of signal integration by the TNF-caspase-8-N4BP1 axis. Together, these aims will provide novel mechanistic
insights explaining a key regulatory circuit underlying inflammation. They also will serve to launch my
independent research career.
项目摘要/摘要
罕见的单基因免疫疾病具有炎症的关键方面,但许多基础
机制仍然很少理解。例如,自身免疫性淋巴增生综合征(ALP),A
T细胞无法发生凋亡的疾病,最常见于死亡接收器中的遗传缺陷引起
FAS或其配体FASL。但是,caspase-8或其适配器FADD中的突变 - 介导细胞死亡
FAS的下游 - 导致阿尔卑斯山和严重的免疫缺陷的组合。由于免疫缺陷是
在FAS或FASL突变的患者中,通常不观察到,我假设FADD-Caspase-8必须具有
除了FAS以外的免疫受体下游的凋亡非依赖性功能。确实,我最近
发现多种免疫接收器的激活引起了caspase-8介导的NEDD4--
结合蛋白1(N4BP1),一种新型的细胞因子抑制剂。这代表了调节期间的关键点
炎。值得注意的是,N4BP1的缺失并不会影响类似TOLL的TRIF依赖性子集
激活caspase-8(例如TLR3和TLR4)的受体(TLR)。但是,细胞因子产生的受损
用TLR4激动剂刺激的caspase-8缺陷巨噬细胞通过N4BP1的共删除恢复到正常状态。
相反,N4BP1缺失导致非依赖性TLR的过高细胞因子反应(例如TLR1/2,
不直接激活caspase-8的TLR7和TLR9)。那就是caspase-8裂解N4BP1使
完整,未切换的N4BP1的抗炎活性。这些发现为
由FADD-Caspase-8突变引起的免疫缺陷,从而无法清除N4BP1导致其
细胞因子反应的异常持久性和收缩。像TLR3和TLR4激动剂一样,肿瘤坏死因子
(TNF)还导致N4BP1的caspase-8裂解,使TNF具有失活N4BP1和
因此,独立于TRIF的TLR的许可细胞因子生产。后来发现这突出了一个关键点
TNF和TLR系统之间的分子串扰在N4BP1的caspase-8裂解上收敛。在
当前的提案,我已将N4BP1抑制细胞因子产生的机制联系起来
具有先前认可的蛋白质和迄今为止未知在炎症中的作用。在AIM 1中,我会尝试
解释了N4BP1控制这种新型激酶依赖性途径的活性的机制
抑制注射。在AIM 2中,我将剖析N4BP1如何抑制后期炎症基因
使用基因组规模技术表达。在AIM 3中,我将探索机制和体内后果
TNF-Caspase-8-N4BP1轴的信号积分。这些目标在一起将提供新颖的机械
洞察力解释了炎症基础的关键调节电路。他们还将发起我的
独立研究职业。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Gitlin其他文献
Alexander Gitlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Gitlin', 18)}}的其他基金
Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
- 批准号:
10337076 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
- 批准号:
10674329 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Molecular Regulation of Germinal Center B Lymphocytes
生发中心 B 淋巴细胞的分子调控
- 批准号:
8649227 - 财政年份:2014
- 资助金额:
$ 44.25万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:82101697
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
NHERF1 regulates MRGPRX2/MrgprB2 responses in mast cells
NHERF1 调节肥大细胞中的 MRGPRX2/MrgprB2 反应
- 批准号:
10711042 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
PTP1b 抑制可恢复化疗期间的先天抗肿瘤反应
- 批准号:
10653166 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别:
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
PTP1b 抑制可恢复化疗期间的先天抗肿瘤反应
- 批准号:
10442910 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别:
Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis
开发 ITCH 激活 IRAK4 降解剂作为治疗类风湿性关节炎的双靶点候选药物
- 批准号:
10545911 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别: